HC Wainwright reissued their buy rating on shares of Kamada (NASDAQ:KMDA - Free Report) in a research note released on Friday,Benzinga reports. The firm currently has a $11.00 price objective on the biotechnology company's stock.
Kamada Trading Up 1.2 %
Shares of NASDAQ:KMDA traded up $0.09 on Friday, hitting $7.41. The company had a trading volume of 515,918 shares, compared to its average volume of 313,003. The stock has a market cap of $425.93 million, a price-to-earnings ratio of 26.46 and a beta of 0.98. The stock has a 50 day moving average price of $6.06 and a 200 day moving average price of $5.67. Kamada has a 1-year low of $4.74 and a 1-year high of $8.00.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Kamada stock. Public Employees Retirement System of Ohio bought a new stake in Kamada Ltd. (NASDAQ:KMDA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,270 shares of the biotechnology company's stock, valued at approximately $77,000. Institutional investors and hedge funds own 20.38% of the company's stock.
Kamada Company Profile
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Read More
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
